Over a decade ago, a dis­as­trous tri­al killed re­search on a po­ten­tial im­munother­a­py. Can a Re­gen­eron bis­pe­cif­ic re­vive it?

In 2006, a Ger­man biotech de­vel­oped what they called a “su­per­ag­o­nist” for CD28, a pock­et on T cells that in the­o­ry could be used to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.